Anal Fissure Treatment Market Report 2025

The anal fissure treatment market size has grown strongly in recent years. It will grow from $1.43 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to limited treatment options, increasing awareness, demographic trends, healthcare infrastructure development, regulatory support.

The anal fissure treatment market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to innovative treatment approaches, rising incidence rates, investment in research and development, patient-centric care, healthcare policy changes. Major trends in the forecast period include technological advancements, increasing demand for minimally invasive procedures, rising incidence of anal fissures, focus on patient-centric approaches, globalization and market expansion.

The burgeoning elderly demographic coupled with unhealthy lifestyle trends is anticipated to act as a driving force for the anal fissure treatment market. As per the World Health Organization (WHO) report in October 2022, it's projected that by 2030, one in six individuals globally will be 60 years or older, rising to a staggering 2.1 billion by 2050. This shift, primarily attributed to age-related factors and detrimental health habits, is foreseen to necessitate increased treatment for anal fissures caused by internal sphincter thinning and tearing.

The increasing prevalence of gastrointestinal disorders is anticipated to drive the growth of the anal fissure treatment market in the coming years. Gastrointestinal disorders, often referred to as digestive disorders, encompass a range of medical conditions that impact the organs and structures of the gastrointestinal (GI) tract. As the incidence of gastrointestinal disorders rises, there is a corresponding increase in the occurrence of anal fissures, leading to greater demand for effective and targeted treatments within the anal fissure treatment market. For example, in September 2023, the National Library of Medicine, a US-based biomedical library managed by the National Institutes of Health (NIH), reported that the overall incidence of Inflammatory Bowel Disease (IBD) in Canada in 2023 is 30 per 100,000, translating to approximately 11,000 new diagnoses of IBD. This incidence is projected to increase by 0.58% annually, reaching 32.1 per 100,000 by 2035. Consequently, the rising incidence of gastrointestinal disorders is propelling the growth of the anal fissure treatment market.

Rising rates of constipation are expected to drive growth in the anal fissure treatment market in the coming years. Constipation is characterized by hard, dry stools that are difficult to pass and infrequent bowel movements. Symptoms may include pain, bloating, discomfort, and lethargy. Damage to the lining of the anus, which commonly occurs in individuals with constipation, can lead to anal fissures, necessitating treatment. Consequently, the growing population experiencing constipation will contribute to market expansion. For instance, in February 2024, according to a report from NHS Digital, a UK-based publication for Members of Parliament, the percentage of children and young people identified with potential eating disorders has increased. In 2023, the prevalence of eating disorders was 2.6% among 11 to 16-year-olds, 12.5% in those aged 17 to 19, and 5.9% for individuals aged 20 to 25. Notably, 12.3% of 11- to 16-year-olds screened positive for eating disorders, compared to 6.7% in 2017. Among 17- to 19-year-olds, the rate was significantly higher, with 59.4% screening positive in 2023, up from 44.6% in 2017. Therefore, the increasing rates of constipation are driving the growth of the anal fissure treatment market.

Prominent entities within the anal fissure treatment market are actively innovating by introducing topical treatments specifically tailored to cater to a larger customer base, drive sales, and bolster revenue streams. Anal fissure topical treatments encompass medicinal applications or ointments directly administered to the affected anal fissure area. Notably, in July 2023, Acrux Limited, a pharmaceutical firm based in Australia, announced the initiation of the United States Food and Drug Administration (FDA) review process for Nitroglycerin Ointment, 0.4%. This product's distinctive feature lies in its efficacy in alleviating moderate to severe pain associated with chronic anal fissures, targeting discomfort stemming from the tear in the anus lining. Acrux Limited focuses on advancing advanced-stage projects set for imminent commercialization while simultaneously making significant strides in the development of earlier-stage products, ensuring a diverse and robust product pipeline.

In January 2024, Merck KGaA, a Germany-based science and technology company specializing in anal fissure treatment, formed a partnership with Inspirna Inc. This collaboration allows Merck KGaA to expand its colorectal cancer portfolio through a licensing agreement for the drug ompenaclid (RGX-202). This first-in-class oral inhibitor targets the creatine transport channel SLC6A8 and is currently in Phase II development for advanced RAS-mutated colorectal cancer (mCRC). Inspirna Inc. is a US-based clinical-stage biopharmaceutical company.

Major companies operating in the anal fissure treatment market include SRS Life Sciences Inc., Healthy Life Pharma Private Limited, Eisai Co. Ltd., AstraZeneca plc, Bayer AG, Novasep Holding S.A.S., Geri-care Pharmaceuticals Corp., Abbott Laboratories, GlaxoSmithKline plc, Valeant Pharmaceuticals International Inc., Taro Pharmaceutical Industries Ltd., Cook Pharmica LLC, Pfizer Inc., Taj Pharmaceuticals Limited, Troikaa Pharmaceuticals Ltd., Purdue Pharma LP, Allergan Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Enobia Pharma Corporation, Alexion Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals Limited, Sanofi S.A., Eli Lilly and Company, Roche Holding AG, Johnson & Johnson Services Inc., AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc.

North America was the largest region in the anal fissure treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the anal fissure treatment market report during the forecast period. The regions covered in the anal fissure treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anal fissure treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anal fissure treatment refers to the process of healing a small tear in the thin, moist tissue that lines the anus, often involving practices such as using sitz baths or taking stool softeners. These treatments aim to soothe sphincter muscles and promote the healing of the anal fissure.

The primary types of anal fissure treatments include topical nitroglycerin, calcium channel blockers, stool softeners, and others. Topical nitroglycerin is an ointment specifically employed for the treatment of chronic anal fissures, effectively reducing moderate to severe discomfort. This medication belongs to the nitrate drug family. The major routes of administration for these treatments include topical and oral methods, and they find application in various healthcare settings such as clinics, hospitals, and others.

The anal fissure treatment market research report is one of a series of new reports that provides anal fissure treatment market statistics, including anal fissure treatment industry global market size, regional shares, competitors with a anal fissure treatment market share, detailed anal fissure treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anal fissure treatment industry. This anal fissure treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anal fissure treatment market includes revenues earned by entities by providing medications such as ointments and therapies for anal fissure. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.